Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/acs.jpclett.0c03615 http://scihub22266oqcxt.onion/10.1021/acs.jpclett.0c03615 33523655!7874498!33523655     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Phys+Chem+Lett 2021 ; 12 (5): 1438-1442 Nephropedia Template TP {{tp|p=33523655|t=2021. Retrained Generic Antibodies Can Recognize SARS-CoV-2 |pdf=|usr=}}{{33523655}} gab.com Text Retrained Generic Antibodies Can Recognize SARS-CoV-2 JO: J Phys Chem Lett http://www.kidney.de/pget.php?&tw=1&pmid=33523655 #FOAvip The dramatic impact novel viruses can have on humans could be more quickly mitigated if generic antibodies already present in one's system are temporarily retrained to recognize these viruses. This type of intervention can be administered during the early stages of infection, while a specific immune response is being developed. With this idea in mind, double-faced peptide-based boosters were computationally designed to allow recognition of SARS-CoV-2 by Hepatitis B antibodies. One booster face is made of ACE2-mimic peptides that can bind to the receptor binding domain (RBD) of SARS-CoV-2. The other booster face is composed of a Hepatitis B core-antigen, targeting the Hepatitis B antibody fragment. Molecular dynamics simulations revealed that the designed boosters have a highly specific and stable binding to both the RBD and the antibody fragment (AF). This approach can provide a cheap and efficient neutralization of emerging pathogens. Twit Text FOAVip Retrained Generic Antibodies Can Recognize SARS-CoV-2 ????J Phys Chem Lett http://www.kidney.de/pget.php?&tw=1&pmid=33523655 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33523655 #FOAvip English Wikipedia <ref>{{Cite pmid|33523655}}</ref> Retrained Generic Antibodies Can Recognize SARS-CoV-2 #MMPMID33523655 Han Y; McReynolds KD; Kral P J Phys Chem Lett 2021[Feb]; 12 (5): 1438-1442 PMID33523655show ga The dramatic impact novel viruses can have on humans could be more quickly mitigated if generic antibodies already present in one's system are temporarily retrained to recognize these viruses. This type of intervention can be administered during the early stages of infection, while a specific immune response is being developed. With this idea in mind, double-faced peptide-based boosters were computationally designed to allow recognition of SARS-CoV-2 by Hepatitis B antibodies. One booster face is made of ACE2-mimic peptides that can bind to the receptor binding domain (RBD) of SARS-CoV-2. The other booster face is composed of a Hepatitis B core-antigen, targeting the Hepatitis B antibody fragment. Molecular dynamics simulations revealed that the designed boosters have a highly specific and stable binding to both the RBD and the antibody fragment (AF). This approach can provide a cheap and efficient neutralization of emerging pathogens. |Amino Acid Sequence[MESH] |Angiotensin-Converting Enzyme 2/chemistry[MESH] |Binding Sites[MESH] |Hepatitis B Antibodies/*chemistry[MESH] |Humans[MESH] |Immunoglobulin Fragments/chemistry[MESH] |Molecular Dynamics Simulation[MESH] |Peptides/chemistry[MESH] |Protein Binding[MESH] |Protein Conformation[MESH] |SARS-CoV-2/*chemistry[MESH] |Single-Chain Antibodies/chemistry[MESH]Retrained Generic Antibodies Can Recognize SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing